Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis

被引：0
|
作者：
Schipilliti, F. M. [1 ]
Rizzo, A. [2 ]
Di Costanzo, F. [3 ]
Acquafredda, S. [4 ]
Arpino, G. [5 ]
Puglisi, F. [6 ]
Del Mastro, L. [7 ]
Montemurro, F. [8 ]
De Laurentiis, M. [9 ]
Giuliano, M. [10 ]
机构：
[1] St Andrea Univ Hosp, Dept Oncol, Rome, Italy
[2] Ist Tumori Bari Giovanni Paolo II IRCCS, Dept Oncol, Bari, Italy
[3] Azienda Osped Univ Federico II, Oncol Med, Naples, Italy
[4] Policlin Bari Osped Giovanni XXIII, Dipartimento Oncol, Bari, Italy
[5] Univ Napoli Federico II, Dept Oncol, Dipartimento Farm, Naples, Italy
[6] Osped S Maria Misericordia, Dept Med Oncol, ASU Friuli Cent, Udine, Pordenone, Italy
[7] IRCCS Osped Policlin San Martino, Dept Internal Med, Genoa, Italy
[8] IRCCS Ist Candiolo FPO, Investigat Clin Oncol Dept, Candiolo, TO, Italy
[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Breast & Thorac Oncol, Naples, Italy
[10] AOU Federico II, Dept Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.463
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
266P
引用
收藏
页码：S289 / S289
页数：1
相关论文
共 50 条
  • [41] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Olga Caramelo
    Cristina Silva
    Francisco Caramelo
    Cristina Frutuoso
    Leonor Pinto
    Teresa Almeida-Santos
    Hereditary Cancer in Clinical Practice, 20
  • [42] Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
    Caramelo, Olga
    Silva, Cristina
    Caramelo, Francisco
    Frutuoso, Cristina
    Pinto, Leonor
    Almeida-Santos, Teresa
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)
  • [43] Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis
    Li, Yunhai
    Yang, Dejuan
    Chen, Ping
    Yin, Xuedong
    Sun, Jiazheng
    Li, Hongzhong
    Ren, Guosheng
    AGING-US, 2019, 11 (16): : 6286 - 6311
  • [44] Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis
    Yu, Yushuai
    Zhang, Jie
    Lin, Yuxiang
    Kang, Shaohong
    Lv, Xinyin
    Song, Chuangui
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1141 - 1151
  • [45] Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
    Mariaelena Pierobon
    Cara L. Frankenfeld
    Breast Cancer Research and Treatment, 2013, 137 : 307 - 314
  • [46] Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis
    Pierobon, Mariaelena
    Frankenfeld, Cara L.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (01) : 307 - 314
  • [47] Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
    Cortes, Javier
    Haiderali, Amin
    Huang, Min
    Pan, Wilbur
    Schmid, Peter
    Akers, Katherine G.
    Park, Julie E.
    Frederickson, Andrew M.
    Fasching, Peter A.
    O'Shaughnessy, Joyce
    BMC CANCER, 2023, 23 (01)
  • [48] Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis
    Liu, Zhilin
    Li, Jinming
    Zhao, Fuxing
    Ren, Dengfeng
    Li, Zitao
    Chen, Yongzhi
    Huang, Shifen
    Liu, Zhen
    Zhao, Yi
    Wang, Miaozhou
    Li, Huihui
    Xu, Zhengbo
    Shen, Guoshuang
    Zhao, Jiuda
    BMC CANCER, 2024, 24 (01)
  • [49] Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
    Javier Cortes
    Amin Haiderali
    Min Huang
    Wilbur Pan
    Peter Schmid
    Katherine G. Akers
    Julie E. Park
    Andrew M. Frederickson
    Peter A. Fasching
    Joyce O’Shaughnessy
    BMC Cancer, 23 (1)
  • [50] Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis
    Latif, Farah
    Jabbar, Hira Bint Abdul
    Malik, Hamna
    Sadaf, Humaira
    Sarfraz, Azza
    Sarfraz, Zouina
    Cherrez-Ojeda, Ivan
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (02) : 229 - 235
12345